ClinicalTrials.gg
RecruitingNCT06981273SPAIN PDUpdated Jul 8, 2026

Robotic vs Open Pancreatoduodenectomy

An interventional study of Robotic pancreatoduodenectomy and open pancreatoduodenectomy in Pancreas Neoplasms, sponsored by Hospital del Mar. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Hospital del Mar · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 202 studies in Pancreatic Neoplasms with a site in Spain — 46 open to participants now, 69 under way, 11 of them phase 3. Pancreatic Neoplasms · Spain.

Planned enrollment
93rd of 174
120 · median 146
Started
2025
with 14 others
No phase
24 of 202
9 open now
Primary completion
2027-09
later than 36 of 68 live
Registered
177th of 202
by date

Among the 202 studies in Pancreatic Neoplasms with a site in Spain, this one is the 93rd largest by planned enrollment of the 174 interventional ones that give a count, is one of 15 that started in 2025, is one of 24 with no phase, reaches primary completion later than 36 of the 68 other live ones, and was the 177th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

46 of the 202 studies in Pancreatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Pancreatic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

Pancreatic surgery, specifically pancreatoduodenectomy (PD), is a complex procedure often required for patients with pancreatic or other periampullary cancers. In recent years, minimally invasive techniques have become more popular, especially robotic-assisted surgery. However, there are limited studies comparing robotic surgery to traditional open surgery.

This is a national, multicenter study in Spain comparing the outcomes of robotic versus open pancreatoduodenectomy (PD). The main goal is to assess complications within 90 days after surgery. This study is important because it will provide evidence on which approach is safer and more effective for patients.

The study follows a **prospective, randomized, and multicenter design**, meaning patients are assigned to either robotic or open surgery randomly, and multiple hospitals are involved. The study will include all eligible patients undergoing planned PD surgery, either by robotic or open technique.

To be included in the study, patients must meet these conditions:

  • Be **18 years or older**.
  • Require **planned PD surgery**.
  • Sign an **informed consent form**.

Who Cannot Participate?

Patients will **not** be included if they:

  • **Refuse the procedure**.
  • Have **uncertainty about vascular involvement**.
  • Have a severe health condition classified as **ASA IV** (high-risk for surgery).

The main outcome measured will be the **Comprehensive Complication Index (CCI), a standardized way to assess post-surgical complications. Additional factors being studied include:

  • **Clinical outcomes** during and after surgery.
  • **Quality of life** assessments.
  • **Surgical costs**.
  • **Hospital stay duration**.
  • **Need to switch from robotic to open surgery**.
  • **Need for additional surgery (reoperations)**.
  • **Hospital readmissions**.

Where Is the Study Being Conducted?

The study is being conducted in **ten major hospitals across Spain**:

  1. Hospital del Mar, Barcelona
  2. Hospital Balmis, Alicante
  3. Hospital Vall d'Hebron, Barcelona
  4. Arnau de Vilanova, Lleida
  5. Joan XXIII, Tarragona
  6. Hospital Sant Pau, Barcelona
  7. HM Sanchinarro, Madrid
  8. Hospital Rio Hortega, Valladolid

How Long Will the Study Last? The study will take **two years** to complete, and patients will be followed for **three years** after surgery to track long-term outcomes.

Why Is This Study Important for Patients? For patients undergoing PD, this study will provide essential information about the risks and benefits of robotic versus open surgery. The findings will help doctors determine the best surgical approach, leading to improved safety, faster recovery, and better long-term health outcomes.

If you are a patient facing this type of surgery, participating in this study could contribute to valuable medical knowledge while ensuring that you receive a carefully monitored treatment plan.

Read the detailed description

Introduction

Pancreatoduodenectomy (PD), commonly known as the Whipple procedure, is a complex surgical procedure used to treat pancreatic, bile duct, and duodenal diseases, including cancer. Traditionally, this surgery has been performed using an open approach (PDA), but recent advancements in minimally invasive techniques have introduced the robotic approach (PDR) as a potential alternative.

Minimally invasive robotic surgery may offer benefits such as reduced blood loss, shorter hospital stays, and potentially lower complication rates. However, there is limited high-quality evidence comparing the outcomes of robotic PD versus open PD. This national, multicenter, randomized clinical trial aims to provide clear answers by analyzing postoperative complications and overall patient outcomes.

Primary Objective

Evaluate postoperative complications using the CCI within 90 days after surgery.

Objectives This clinical trial aims to compare two different surgical approaches, PDR and PDA, in relation to postoperative morbidity within 90 days following surgery. Morbidity is assessed using the Complication Index (CCI) (www.assesssurgery.com). The primary objective is to measure CCI®, which tracks complications up to 90 days after surgery. Secondary objectives include intraoperative variables (e.g., blood loss, operative time, and conversion), postoperative morbidity (e.g., pancreatic-specific complications as defined by ISGPS), oncological outcomes in cases of malignancy (radicality, lymph node removal, and time until adjuvant chemotherapy), healthcare resource utilization (length of stay, readmissions, ICU stay), and quality of life and recovery post-surgery.

Secondary Objectives

Intraoperative outcomes: Blood loss, operative time, and conversion rates from robotic to open surgery.

Postoperative morbidity: Evaluated using the International Study Group of Pancreatic Surgery (ISGPS) definitions.

Oncological outcomes (for cancer patients): Tumor clearance, number of lymph nodes removed, and time to adjuvant chemotherapy.

Healthcare resource utilization: Hospital stay, ICU admission, and hospital readmissions.

Quality of life and recovery after surgery.

Hypothesis The PDR surgical procedure demonstrates non-inferiority in the post-operative CCI score up to 90 days after surgery.

Materials and Methods

Study Design

This is a national, multicenter, randomized, prospective clinical trial with parallel groups comparing patients undergoing PD for any cause. Patients will be randomized into two groups:

Group 1: PDR Group 2: PDA The study will span 2 years. The research will be conducted in centers with an annual volume of at least 30 pancreatic resections (distal and cephalic) and surgeons with personal experience of at least 30 PDRs annually. A minimum of 30 pancreatic resections includes at least 20 pancreatoduodenectomies annually.

Sample Size This is a non-inferiority 2:1 study. According to previous studies, a clinically relevant mean difference in CCI is 7.5, while the average standard deviation is approximately 20 in major abdominal surgeries. A total of 120 patients will need to be enrolled in the trial (40 open group and 80 for robotic group), accounting for a 5% dropout rate, with an alpha error of 5% and a beta error of 20%.

Data Collection

Clinical Data Postoperative complications will be classified and evaluated according to the Clavien-Dindo classification (I to V) and the CCI numeric scale (www.assesssurgery.com). Major complications are those rated IIIa or higher. Complications, readmissions, and mortality will be measured up to 90 days.

Safety Assessment of Procedures

Both techniques, PDR and PDA, will be evaluated for adverse events. The following complications will be recorded in the Clinical Data Record (CRD):

Blood loss and need for transfusion during the procedure Postoperative hemorrhage Postoperative transfusion Biliary fistula Need for re-intervention Need for readmission Postoperative death Economic Data Economic data will be collected based on the single cost assigned to each procedure, calculated using the RECH system (Spanish Hospital Cost Network: https://www.rechosp.org). The costs will be derived from the National Health System's (SNS) diagnostic-related groups (DRG). The total cost will be calculated by multiplying the number of resource units used by the unit cost.

Measures to Minimize Bias Two main limitations are anticipated. The first concerns variability in surgical techniques among the surgeons. To minimize this, a meeting of all participating centers will be held to standardize surgical techniques. Furthermore, quality control will involve sending a video of the PDR procedure from each surgeon for evaluation.

The second limitation relates to patient recruitment. To address this, a conservative estimate of potential candidates was made, and centers with high volumes of pancreatic resections (at least 30 per year, including 20 pancreatoduodenectomies) have been selected.

Randomization Randomization will be performed using block assignment stratified by center, ensuring balanced groups within each participating hospital. Randomization between the robotic and open arms will occur before surgery with a 2:1 ratio (2 Robotic and 1 Open) using an online system.

Blinding This study will be single-blinded, meaning patients will not be aware of which group they belong to. After surgery, a cover will be applied to the abdominal wall so patients cannot see whether they had a robotic or open procedure.

Surgical Procedures

PDA:

The procedure begins with a bilateral subcostal incision. After initial exploration, if no distant disease is found, a PD will be performed. Reconstruction follows after the surgical specimen is removed.

PDR:

The procedure starts with robotic trocar placement, along with up to two additional laparoscopic trocars. Surgical steps follow the PDA procedure, but the specimen is removed through a mini-incision. Hybrid techniques (laparoscopic resection and robotic reconstruction) are excluded.

Data Recording Study variables will be stored in an online data collection form (CRD), which will automatically transfer data to a database. The system used for this will be Red Cap. The investigators and study monitor will have digital access to the Red Cap database to include new patients and review data during follow-up. Patient names will not appear in the database to ensure confidentiality. A subject code will be used for anonymity, and an identification register will link the code to the patient's medical record.

Statistical Analysis Data will be analyzed using IBM SPSS Statistics for Windows version 24.0 (IBM Corp.). Statistical tests such as Student's T-test, Mann-Whitney U test, Chi-square, and Fisher's exact test will be employed. Categorical data will be presented as frequency and percentage, and continuous data as mean, standard deviation, or median with interquartile range. Subgroups will be analyzed using Chi-square, Mann-Whitney U, and Kruskal-Wallis tests, with p\<0.05 indicating statistical significance.

Ethical Aspects The study will be registered on www.controlled-trials.com and will follow the ethical principles of the Declaration of Helsinki (2013) and Good Clinical Practice (GCP). Informed consent will be obtained from all participants, and the study will be reviewed by an Ethics Committee. The protocol will be registered on clinicaltrial.gov. Confidentiality will be maintained, and data will not be shared with third parties without consent.

Sample Management and Confidentiality Only necessary biological samples will be taken, with all patient data stored pseudonymized to ensure confidentiality. The study will comply with GDPR and local privacy laws.

Funding Funding for the study will be requested from the Spanish Association of Surgeons (AEC) for a total of €10,000, which will be used for insurance and monitoring.

Monitoring and Auditing The study will be monitored by clinical investigators and a data manager for periodic center audits.

Public Disclosure and Publication Results will be submitted to a high-impact medical journal, with authorship based on participant center recruitment volume. The study's findings will also be published in scientific journals following local regulations.

03

Conditions studied

  • Pancreas Neoplasms

Keywords

  • Robotic
  • pancreaticoduodenectony
  • Robotic surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Patients requiring planned pancreatoduodenectomy (robotic or open).
  • Signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse the procedure.
  • Uncertainty about vascular involvement that could affect resectability.
  • Poor general health status ( [ASA] classification IV).
  • Pancreatitis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Robotic

    Robotic pancreatoduodenectomy is performed under the robotic da Vinci system where at least the pancreatic and biliary anastomosis is performed throughout this approach.

    Procedure: Robotic pancreatoduodenectomy

  • Active comparator
    Open

    open pancreatoduodenectomy is performed through a laparotomy following the standard criteria for this type of surgery.

    Procedure: open pancreatoduodenectomy

Interventions

  • ProcedureRobotic pancreatoduodenectomy

    A Robotic approach pancreatoduodenectomy is performed on patients

  • Procedureopen pancreatoduodenectomy

    An open approach for pancreatoduodenectomy is performed

06

What researchers measure

Primary outcomes

  1. Complication Index

    Morbidity is assessed using the Complication Index (CCI) (www.assesssurgery.com). The primary objective is to measure CCI®, which tracks complications up to 90 days after surgery.

    Time frame: up to 90 days after surgery

Secondary outcomes

  1. Cost effectiveness

    Economic data will be collected based on the single cost assigned to each procedure, calculated using the RECH system (Spanish Hospital Cost Network: https://www.rechosp.org). The costs will be derived from the National Health System's (SNS) diagnostic-related groups (DRG). The total cost will be calculated by multiplying the number of resource units used by the unit cost. Effectiveness will be used with the EQ-5D-5L using the QALY model

    Time frame: 3 months after surgery

  2. Tumor clearance

    pancreatic stump margins defined as R0, R1 or R2

    Time frame: until the end of the study

  3. operative time

    Duration of the operation in minutes.

    Time frame: during the surgery

  4. Blood loss

    intraoperative blood loss in ml

    Time frame: during the surgery

  5. Conversion to open surgery

    This is only for the robotic approach where conversion to open occurred

    Time frame: during surgery

  6. Pancreatic Fistula

    collection of data of pancreatic fistula according to International Study Group of Pancreatic Surgery (ISGPS) : Type A, B or C

    Time frame: after surgery up to 90 days from operation

  7. EORTC QLQ-C30

    scale of quality if life

    Time frame: before and after surgery at 30 and 90 days

  8. QoR-15

    test of quality of recuperation after surgery

    Time frame: after surgery at 30 and 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CM, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584-591. doi: 10.1016/j.surg.2016.11.014. Epub 2016 Dec 28. PubMed 28040257 ↗
  • Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, Oberkofler CE, Graf R, Puhan MA, Clavien PA. The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials. Ann Surg. 2014 Nov;260(5):757-62; discussion 762-3. doi: 10.1097/SLA.0000000000000948. PubMed 25379846 ↗
  • van Hilst J, de Graaf N, Abu Hilal M, Besselink MG. The Landmark Series: Minimally Invasive Pancreatic Resection. Ann Surg Oncol. 2021 Mar;28(3):1447-1456. doi: 10.1245/s10434-020-09335-3. Epub 2020 Dec 19. PubMed 33341916 ↗
  • Boggi U, Signori S, De Lio N, Perrone VG, Vistoli F, Belluomini M, Cappelli C, Amorese G, Mosca F. Feasibility of robotic pancreaticoduodenectomy. Br J Surg. 2013 Jun;100(7):917-25. doi: 10.1002/bjs.9135. PubMed 23640668 ↗
  • Tran TB, Dua MM, Worhunsky DJ, Poultsides GA, Norton JA, Visser BC. The First Decade of Laparoscopic Pancreaticoduodenectomy in the United States: Costs and Outcomes Using the Nationwide Inpatient Sample. Surg Endosc. 2016 May;30(5):1778-83. doi: 10.1007/s00464-015-4444-y. Epub 2015 Aug 15. PubMed 26275542 ↗
  • Jones LR, Zwart MJW, Molenaar IQ, Koerkamp BG, Hogg ME, Hilal MA, Besselink MG. Robotic Pancreatoduodenectomy: Patient Selection, Volume Criteria, and Training Programs. Scand J Surg. 2020 Mar;109(1):29-33. doi: 10.1177/1457496920911815. PubMed 32192422 ↗
  • van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, Gerhards MF, de Hingh IH, Karsten TM, Lips DJ, Luyer MD, Busch OR, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):199-207. doi: 10.1016/S2468-1253(19)30004-4. Epub 2019 Jan 24. PubMed 30685489 ↗
  • Wang M, Li D, Chen R, Huang X, Li J, Liu Y, Liu J, Cheng W, Chen X, Zhao W, Li J, Tan Z, Huang H, Li D, Zhu F, Qin T, Ma J, Yu G, Zhou B, Zheng S, Tang Y, Han W, Meng L, Ke J, Feng F, Chen B, Yin X, Chen W, Ma H, Xu J, Liu Y, Lin R, Dong Y, Yu Y, Liu J, Zhang H, Qin R; Minimally Invasive Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare (MITG-P-CPAM). Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):438-447. doi: 10.1016/S2468-1253(21)00054-6. Epub 2021 Apr 27. PubMed 33915091 ↗
  • Poves I, Burdio F, Morato O, Iglesias M, Radosevic A, Ilzarbe L, Visa L, Grande L. Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy: The PADULAP Randomized Controlled Trial. Ann Surg. 2018 Nov;268(5):731-739. doi: 10.1097/SLA.0000000000002893. PubMed 30138162 ↗
  • Kendrick ML, van Hilst J, Boggi U, de Rooij T, Walsh RM, Zeh HJ, Hughes SJ, Nakamura Y, Vollmer CM, Kooby DA, Asbun HJ; Minimally Invasive Pancreatic Resection Organizing Committee. Minimally invasive pancreatoduodenectomy. HPB (Oxford). 2017 Mar;19(3):215-224. doi: 10.1016/j.hpb.2017.01.023. PubMed 28317658 ↗
  • de Rooij T, van Hilst J, Topal B, Bosscha K, Brinkman DJ, Gerhards MF, de Hingh IH, Karsten TM, Lips DJ, Luyer MD, Marsman HA, van Rijssen LB, Steen MW, Busch OR, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. Outcomes of a Multicenter Training Program in Laparoscopic Pancreatoduodenectomy (LAELAPS-2). Ann Surg. 2019 Feb;269(2):344-350. doi: 10.1097/SLA.0000000000002563. PubMed 29099400 ↗
  • de Rooij T, Lu MZ, Steen MW, Gerhards MF, Dijkgraaf MG, Busch OR, Lips DJ, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Pancreatoduodenectomy: Systematic Review and Meta-analysis of Comparative Cohort and Registry Studies. Ann Surg. 2016 Aug;264(2):257-67. doi: 10.1097/SLA.0000000000001660. PubMed 26863398 ↗
  • Jin T, Altaf K, Xiong JJ, Huang W, Javed MA, Mai G, Liu XB, Hu WM, Xia Q. A systematic review and meta-analysis of studies comparing laparoscopic and open distal pancreatectomy. HPB (Oxford). 2012 Nov;14(11):711-24. doi: 10.1111/j.1477-2574.2012.00531.x. Epub 2012 Aug 7. PubMed 23043660 ↗
  • Klotz R, Mihaljevic AL, Kulu Y, Sander A, Klose C, Behnisch R, Joos MC, Kalkum E, Nickel F, Knebel P, Pianka F, Diener MK, Buchler MW, Hackert T. Robotic versus open partial pancreatoduodenectomy (EUROPA): a randomised controlled stage 2b trial. Lancet Reg Health Eur. 2024 Feb 22;39:100864. doi: 10.1016/j.lanepe.2024.100864. eCollection 2024 Apr. PubMed 38420108 ↗
  • de Graaf N, Emmen AMLH, Ramera M, Bjornsson B, Boggi U, Bruna CL, Busch OR, Daams F, Ferrari G, Festen S, van Hilst J, D'Hondt M, Ielpo B, Keck T, Khatkov IE, Koerkamp BG, Lips DJ, Luyer MDP, Mieog JSD, Morelli L, Molenaar IQ, van Santvoort HC, Sprangers MAG, Ferrari C, Berkhof J, Maisonneuve P, Abu Hilal M, Besselink MG; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally invasive versus open pancreatoduodenectomy for pancreatic and peri-ampullary neoplasm (DIPLOMA-2): study protocol for an international multicenter patient-blinded randomized controlled trial. Trials. 2023 Oct 12;24(1):665. doi: 10.1186/s13063-023-07657-7. PubMed 37828593 ↗
  • Asbun HJ, Moekotte AL, Vissers FL, Kunzler F, Cipriani F, Alseidi A, D'Angelica MI, Balduzzi A, Bassi C, Bjornsson B, Boggi U, Callery MP, Del Chiaro M, Coimbra FJ, Conrad C, Cook A, Coppola A, Dervenis C, Dokmak S, Edil BH, Edwin B, Giulianotti PC, Han HS, Hansen PD, van der Heijde N, van Hilst J, Hester CA, Hogg ME, Jarufe N, Jeyarajah DR, Keck T, Kim SC, Khatkov IE, Kokudo N, Kooby DA, Korrel M, de Leon FJ, Lluis N, Lof S, Machado MA, Demartines N, Martinie JB, Merchant NB, Molenaar IQ, Moravek C, Mou YP, Nakamura M, Nealon WH, Palanivelu C, Pessaux P, Pitt HA, Polanco PM, Primrose JN, Rawashdeh A, Sanford DE, Senthilnathan P, Shrikhande SV, Stauffer JA, Takaori K, Talamonti MS, Tang CN, Vollmer CM, Wakabayashi G, Walsh RM, Wang SE, Zinner MJ, Wolfgang CL, Zureikat AH, Zwart MJ, Conlon KC, Kendrick ML, Zeh HJ, Hilal MA, Besselink MG; International Study Group on Minimally Invasive Pancreas Surgery (I-MIPS). The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Ann Surg. 2020 Jan;271(1):1-14. doi: 10.1097/SLA.0000000000003590. PubMed 31567509 ↗
  • Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Yeo CJ, Buchler MW. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007 Jul;142(1):20-5. doi: 10.1016/j.surg.2007.02.001. PubMed 17629996 ↗
  • Hirata K, Egawa S, Kimura Y, Nobuoka T, Oshima H, Katsuramaki T, Mizuguchi T, Furuhata T. Current status of surgery for pancreatic cancer. Dig Surg. 2007;24(2):137-47. doi: 10.1159/000102067. Epub 2007 Apr 27. PubMed 17476103 ↗
  • Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004 Apr;28(3):219-30. doi: 10.1097/00006676-200404000-00002. PubMed 15084961 ↗
  • Carrancho A, Vinci D, Burdio F, Sanchez-Velazquez P, Ielpo B; SPAIN Trial group. Robotic versus open pancreatoduodenectomy (SPAIN Trial): protocol for a multicenter randomized controlled trial assessing safety, efficacy and cost-effectiveness. Updates Surg. 2026 Jun 9. doi: 10.1007/s13304-026-02574-1. Online ahead of print. PubMed 42262715 ↗

Individual participant data

Plan to share: No — I do not want to be contacted by commercial industry regarding this study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2025
First posted
May 20, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06981273
Lead sponsor
Hospital del Mar
Responsible party
Benedetto Ielpo (prof, Hospital del Mar) — Principal investigator
First posted
May 20, 2025
Start date
Sep 1, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Benedetto Ielpo, PhD, MD, FACS, FEBS
Contact
bielpo@hmar.cat
0034 932 48 30 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion